Posted by Michael Wonder on 11 Dec 2021
Junshi Biosciences announces NMPA accepted supplemental new drug application for toripalimab in combination with chemotherapy as first-line treatment of advanced NSCLC
10 December 2021 - Sixth indication for toripalimab submitted in China.
Junshi Biosciences announced today that the National Medical Products Administration has accepted the company’s supplemental new drug application for toripalimab in combination with chemotherapy as the first-line treatment of patients with treatment-naive advanced or metastatic non-small cell lung cancer with no EGFR or ALK tumour aberrations.
